NO974943L - Angiostatinfragmenter, aggregert angiostatin og anvendelse derav - Google Patents

Angiostatinfragmenter, aggregert angiostatin og anvendelse derav

Info

Publication number
NO974943L
NO974943L NO974943A NO974943A NO974943L NO 974943 L NO974943 L NO 974943L NO 974943 A NO974943 A NO 974943A NO 974943 A NO974943 A NO 974943A NO 974943 L NO974943 L NO 974943L
Authority
NO
Norway
Prior art keywords
angiostatin
fragments
proliferation inhibitor
aggregated
aggregate
Prior art date
Application number
NO974943A
Other languages
English (en)
Norwegian (no)
Other versions
NO974943D0 (no
Inventor
Moses Judah Folkman
Michael S O'reilly
Yihai Cao
Jie Lin
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/429,743 external-priority patent/US5885795A/en
Priority claimed from US08/605,598 external-priority patent/US5861372A/en
Priority claimed from US08/612,788 external-priority patent/US5837682A/en
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Publication of NO974943D0 publication Critical patent/NO974943D0/no
Publication of NO974943L publication Critical patent/NO974943L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
NO974943A 1995-04-26 1997-10-24 Angiostatinfragmenter, aggregert angiostatin og anvendelse derav NO974943L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/429,743 US5885795A (en) 1994-04-26 1995-04-26 Methods of expressing angiostatic protein
US08/605,598 US5861372A (en) 1996-02-22 1996-02-22 Aggregate angiostatin and method of use
US08/612,788 US5837682A (en) 1996-03-08 1996-03-08 Angiostatin fragments and method of use
PCT/US1996/005856 WO1996035774A2 (en) 1995-04-26 1996-04-26 Angiostatin fragments and aggregate angiostatin and methods of use

Publications (2)

Publication Number Publication Date
NO974943D0 NO974943D0 (no) 1997-10-24
NO974943L true NO974943L (no) 1997-12-18

Family

ID=27411639

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974943A NO974943L (no) 1995-04-26 1997-10-24 Angiostatinfragmenter, aggregert angiostatin og anvendelse derav

Country Status (17)

Country Link
EP (1) EP0824546B1 (ja)
JP (2) JP3787157B2 (ja)
CN (1) CN1195375A (ja)
AT (1) ATE368051T1 (ja)
AU (1) AU709633B2 (ja)
BR (1) BR9608326A (ja)
CA (1) CA2219081C (ja)
CZ (1) CZ334097A3 (ja)
DE (1) DE69637179T2 (ja)
ES (1) ES2292174T3 (ja)
HK (1) HK1002457A1 (ja)
HU (1) HUP9800784A3 (ja)
MX (1) MX9708217A (ja)
NO (1) NO974943L (ja)
NZ (1) NZ307044A (ja)
PL (1) PL323256A1 (ja)
WO (1) WO1996035774A2 (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU710612B2 (en) * 1995-12-13 1999-09-23 Abbvie Inc. Endothelial cell proliferation inhibitor and method of use
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US5801012A (en) 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
WO1999016889A1 (en) * 1997-10-01 1999-04-08 G.D. Searle & Co. Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
WO1999026480A1 (en) * 1997-11-20 1999-06-03 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
US6797488B1 (en) 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
CN1284134A (zh) * 1997-12-08 2001-02-14 贝斯以色列护理医疗中心 利用毕赤氏酵母表达系统生产抗生血管蛋白质∶制管张素,内抑制素或静息蛋白的方法
CA2263784A1 (en) * 1998-03-23 1999-09-23 Megabios Corporation Dual-tagged proteins and their uses
DK1074264T3 (da) * 1998-04-28 2008-11-24 Toshikazu Nakamura Inhibitorer for neovaskularisering
AU3959499A (en) * 1998-05-28 1999-12-13 Korea Green Cross Corporation Process of purifying angiogenesis inhibitors
AU762615B2 (en) 1998-06-15 2003-07-03 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
US6201104B1 (en) * 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2000044391A2 (en) * 1999-01-28 2000-08-03 The Children's Medical Center Corporation Plasminogen kringle 4 region fragments and methods of use
US7157556B1 (en) 1999-02-10 2007-01-02 The Children's Medical Center Corporation Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use
EP1153125B1 (en) * 1999-02-10 2007-04-18 The Children's Medical Center Corporation Deglycosylated kringle 1-5 region fragments of plasminogen and methods of use
PE20020376A1 (es) * 2000-09-29 2002-05-13 Abbott Lab Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
CA2480809A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
CN1946430B (zh) * 2004-01-09 2012-03-21 财团法人牧岩生命工学研究所 包含人载脂蛋白(a)三环lk68或lk8基因作为有效成分用于治疗癌症的治疗剂,以及使用其治疗癌症的方法
WO2005079835A1 (ja) * 2004-02-24 2005-09-01 Ttc Co., Ltd. Ｂｌアンジオスタチンを含む制がん剤
ITMI20041962A1 (it) * 2004-10-15 2005-01-15 Istituto Naz Per La Ricerca S "peptide di angiostatina e suoi impieghio terapeutici"
CN101219219B (zh) * 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
WO2010070746A1 (ja) * 2008-12-17 2010-06-24 株式会社ティムス イヌアンジオスタチン様ポリペプチド
JP5749229B2 (ja) * 2012-07-31 2015-07-15 京セラドキュメントソリューションズ株式会社 ジェスチャー管理プログラム及び情報処理装置
US11090372B2 (en) 2015-12-18 2021-08-17 Talengen International Limited Method of treating diabetic nephropathy comprising administering plasminogen
CN106890324A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
WO2018107702A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种治疗糖尿病的新方法
WO2019043649A2 (en) * 2017-08-31 2019-03-07 Singapore Health Services Pte Ltd ANGIO -3 FOR THE TREATMENT OF RETINAL ANGIOGENIC DISEASES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3880064B2 (ja) * 1994-04-26 2007-02-14 ザ チルドレンズ メディカル センター コーポレイション アンジオスタチンおよび血管形成の抑制におけるその使用

Also Published As

Publication number Publication date
MX9708217A (es) 1997-12-31
WO1996035774A3 (en) 1997-02-13
EP0824546B1 (en) 2007-07-25
BR9608326A (pt) 2000-03-08
HUP9800784A3 (en) 2000-07-28
ATE368051T1 (de) 2007-08-15
DE69637179T2 (de) 2008-04-10
ES2292174T3 (es) 2008-03-01
JP3787157B2 (ja) 2006-06-21
WO1996035774A2 (en) 1996-11-14
CZ334097A3 (cs) 1998-04-15
AU709633B2 (en) 1999-09-02
HK1002457A1 (en) 1998-08-28
AU5579596A (en) 1996-11-29
NO974943D0 (no) 1997-10-24
CA2219081A1 (en) 1996-11-14
HUP9800784A2 (hu) 1998-07-28
CN1195375A (zh) 1998-10-07
EP0824546A2 (en) 1998-02-25
JPH11508228A (ja) 1999-07-21
PL323256A1 (en) 1998-03-16
NZ307044A (en) 2002-03-01
JP2001151691A (ja) 2001-06-05
CA2219081C (en) 2004-02-24
DE69637179D1 (de) 2007-09-06

Similar Documents

Publication Publication Date Title
NO974943D0 (no) Angiostatinfragmenter, aggregert angiostatin og anvendelse derav
CA2291892A1 (en) Angiostatin fragments and method of use
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
MXPA00004256A (es) Inhibidor de las celulas endoteliales vasculares, un inhibidor de la angiogenesis y crecimiento del tumor.
ES2169864T3 (es) Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.
EA199900162A1 (ru) Ингибиторы клеточной адгезии
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
NO961888L (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser
PT991619E (pt) Inibidores da adesao celular mediada pela alfa4beta1
ATE354372T1 (de) Verwendung von mif-antagonisten zur krebstherapie
NO990086D0 (no) Avkortete, oppl÷selige tumornekrosefaktorreseptorer av type I og type II
PL327181A1 (en) Benzofurane carboxyamides and sulphonamides
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
ATE211921T1 (de) Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata
DE69912743D1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges
WO1999057133A3 (en) Inhibitors of nf-kb activation
WO2000044391A3 (en) Plasminogen kringle 4 region fragments and methods of use
DE69431603D1 (de) Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins
IS5613A (is) Notkun CD137 til að stuðla að fjölgun jaðar-einkjörnunga
ATE239076T1 (de) Zielspezifische abgabe zum nukleus mittels protein h von streptococcus
ATE294590T1 (de) Verwendung von interleukin-11 zur behandlung von hämoragischem schock
ES2119581A1 (es) Utilizacion de fragmentos de timosina y/o sus derivados
DE60012718D1 (de) Prognose von ptp lar vermittelten krankheiten
NZ332903A (en) Angiostatin fragments and aggregate angiostatin and methods for inhibiting endothelial cell proliferation
UA16958A1 (uk) Ультразвуковий перетворювач

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application